Company: REVB
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000950170-25-105284
Chunk: 7

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 7
---
 continue to complete all necessary product development or future commercialization efforts. We have never generated revenue and do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for Product Candidates or other product candidates, which we expect will not be for at least several years, if ever. We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one-year after the date that our audited financial statements for June 30, 2025 were issued, which raises substantial doubt about our ability to continue as a going concern.

To continue as a going concern, we will need, among other things, to raise additional capital resources. We plan to seek additional funding through public or private equity or debt financings. We may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. If we are unable to obtain funding we could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business operations.

The unaudited consolidated financial statements for June 30, 2025, have been prepared on the basis that we will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for us to continue as a going concern.

Cash Flows

The following table summarizes our cash flows for the periods presented:

                                                            Six Months Ended                                            
                                                            June 30,                                                    
                                                            2025                                  2024                  
  Net cash used in operating activities                     $                     (4,713,688      $         (5,316,651  
  Net cash used in investing activities                                                    -                   (19,172  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net cash provided by financing activities                                        3,388,541                 5,417,180  
  Net (decrease) increase in cash and cash equivalents      $                     (1,325,147      $             81,357  

Net Cash Used in Operating Activities

During the six months ended June 30, 2025, net cash used in operating activities was $4.7 million, which consisted of a net loss of $4.5 million and a net change of $0.2 million comprised of the change in fair value